Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose ropinirole PR dose–response in early Parkinson's disease
2011-002827-17Phase 4Completed
- Sponsor
- GSK
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ropinirole in Parkinson's disease (PD), sponsored by GSK. Primary endpoint: Change from baseline in UPDRS motor score at Week 4 of the Maintenance period. Started Feb 2013; status: completed.
02
Drugs
ropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2011-002827-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002827-17.